Contact your provider if: you discover a concentration mismatch after one or more injections, experience unexpected side effects that do not align with your dose level, receive a vial without clear concentration labeling, switch pharmacies and receive a different concentration than expected, suspect you administered too much or too little medication, or experience no therapeutic effects after four or more weeks at your current dose
Incorrect reconstitution can result in particle formation, incorrect concentration, or pH changes that all affect injection comfort
Wegovy (semaglutide 2.4 mg) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities
At the height of semaglutide shortages in 2023, experts from the American Diabetes Association published recommendations around how to prescribe lower doses for patients with diabetes
No funny business-like MRSA or mercury